Amarin Makes Flawed Argument In Bid To Drain Omega-3 Market – CRN
This article was originally published in The Rose Sheet
Executive Summary
CRN recommends the International Trade Commission not investigate Amarin's complaint against dietary supplements containing primarily ethyl ester or re-esterified EPA. The firm markets Vascepa, a synthetically produced ethyl ester drug approved to reduce triglyceride levels in adults with severe hypertriglyceridemia.